Barinthus Bio and Clywedog Therapeutics Announce Definitive Merger Agreement to Create Nasdaq-Listed Clywedog Therapeutics, Inc.

The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are bei...

October 01, 2025 | Wednesday | News
ADvantage Therapeutics Secures $2.5M NIH Grant to Advance Alzheimer’s Candidate AD04®

ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 mil...

September 30, 2025 | Tuesday | News
Lupin to Acquire VISUfarma from GHO Capital, Expanding Ophthalmology Footprint in Europe

Global pharma major Lupin Limited (Lupin), announced its wholly owned subsidiary, Nanomi B.V. ('Nanomi'), has signed a definitive agreement for the acquisi...

September 29, 2025 | Monday | News
AstraZeneca Launches AstraZeneca Direct to Expand Affordable Access to Medicines with Home Delivery

AstraZeneca announces the launch of AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access th...

September 29, 2025 | Monday | News
Eisai and Biogen Gain Australian Approval for LEQEMBI® in Early Alzheimer’s Disease

Eisai Co., Ltd. and Biogen Inc. announced that the Therapeutic Goods Administration (TGA) of Australia has approved LEQEMBI® (lecanemab), a humanized...

September 25, 2025 | Thursday | News
Booking Health Expands Access to Stage 4 Cancer Treatment in Germany

Booking Health, a leading medical travel facilitator, has announced the expansion of its oncology services to improve international access to advanced st...

September 25, 2025 | Thursday | News
Ncardia Launches First iPSC-Derived Non-Human Primate Cardiomyocytes for Translational Cardiac Research

-Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment,  announced the launch of Ncyte® NHP-C vCardiomyo...

September 24, 2025 | Wednesday | News
Remedium Bio and Eli Lilly Enter Multi-Target Gene Therapy Collaboration in Type 2 Diabetes and Obesity

Lifespan Vision Ventures is pleased to announce that its portfolio company, Remedium Bio, Inc. ("Remedium"), has entered into a multi-target research and...

September 24, 2025 | Wednesday | News
Rise Therapeutics Expands Oral Dendritic Cell Modulator Program into Sjögren’s Disease Following Positive RA Clinical Data

Supported by recent clinical data from the first-ever clinical study of an oral dendritic cell (DC) modulator in rheumatoid arthritis (RA), Rise Therapeu...

September 24, 2025 | Wednesday | News
Yatiri Bio Secures Gates Foundation Grant to Advance Proteomics Interoperability for Global Health

Yatiri Bio Inc.  announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at imp...

September 23, 2025 | Tuesday | News
Australia’s Immutep and GW Cancer Center Launch Phase II Trial of Efti in Early-Stage HR+/HER2-Negative Breast Cancer

GW Cancer Center to initiate Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in HR+/HER...

September 23, 2025 | Tuesday | News
Pfizer Tucks Into $4.9 Billion Metsera Feast — Because Nothing Says Slimming Like Bulking Up

  Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valu...

September 23, 2025 | Tuesday | News
Sunflower Therapeutics and SK bioscience Achieve First Milestone in Development of Cost-Effective 10-Valent HPV Vaccine

 Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applic...

September 19, 2025 | Friday | News
Thermo Fisher Scientific Launches Olink® Target 48 Neurodegeneration Panel for Absolute Quantification of Key Biomarkers

Targeted proteomics panel delivers absolute quantification of key and emerging biomarkers in one scalable assay Thermo Fisher Scientific Inc., the world...

September 16, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close